DNA end resection is a key step in homologous recombination-mediated DNA repair. The ability to manipulate resection capacity is expected to be a powerful strategy to rationally modulate DNA repair outcomes in cancer cells and induce selective cell lethality. However, clinically compatible strategies to manipulate resection are not yet well established. Here we find that long-term inhibition of the ATR kinase has a drastic effect on DNA end resection. Inhibition of ATR over multiple cell division cycles depletes the pool of pro-resection factors and prevents RAD51 as well as RAD52-mediated DNA repair, leading to toxic end-joining and hypersensitivity to PARP inhibitors. The effect is markedly distinct from acute ATR inhibition, which blocks RAD51-mediated repair but not resection and RAD52mediated repair. Our findings reveal a key pro-resection function for ATR and define how ATR inhibitors can be used for effective manipulation of DNA end resection capacity and DNA repair outcomes in cancer cells.
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Results
Chemical and genetic ablation of ATR signaling depletes the abundance of key resection factors
We have previously shown that long-term treatment with the ATR inhibitor (ATRi) VE-821 severely depletes the abundance of HR factors and reduces HR capacity in cancer cells 17 . Here, using two distinct ATR inhibitors, VE-821, and AZD6738, we find that the abundance of three central resections factors, BRCA1, BLM and, CTIP, is strongly reduced by long-term ATR inhibition in U-2OS cells (Figs. 1a-d). Of importance, only minor alterations in cell cycle distribution were observed under the conditions used ( Fig. 1e) , indicating that the observed changes in protein abundance are not due to the indirect effects of a cell cycle arrest. To further confirm that the diminished abundance of DNA end resection factors was caused by loss of ATR signaling, we monitored the abundance of these proteins upon genetic ablation of the ATR activators TOPBP1 and ETAA1. We used an HCT116-derivative cell line where the ATR Activating Domain (AAD) in the ETAA1 gene has been removed by CRISPR-Cas9, and both alleles of TOPBP1 were tagged with an mAID epitope to conditionally induce TOPBP1 degradation upon auxin treatment 44, 45 (Fig. 1f ). TOPBP1 auxin-dependent degradation resulted in destabilized BRCA1, BLM, and CTIP ( Fig. 1g ), similar to the effect observed with ATRi treatment. The abundance of resection factors was restored after auxin washout, indicating that loss of resection capacity is transient and is caused by the temporary and reversible suppression of ATR signaling (Fig.   1h ). Importantly, auxin-induced TOPBP1 depletion did not alter the cell cycle distribution (Fig. 1i ).
Taken together, these results show that ATR signaling plays a key role in maintaining the abundance of crucial pro-resection factors. Since genotoxins are not used in the described experiments, the findings suggest that the maintenance of resection factor abundance relies on intrinsic ATR activation. Furthermore, since acute treatment (up to 24 hours) with ATR inhibitors does not result in similar depletion of resection factors, the activity of ATR must be inhibited over multiple cell division cycles for the altered abundances to become noticeable.
Long-term ATR inhibition severely impairs DNA end resection
Based on the results above, we predicted that long-term ATR inhibition leads to a strong decrease in DNA end resection efficiency. To test this, we used an engineered system to introduce DSBs at a defined genomic locus through CRISPR-Cas9 technology and measured nearby ssDNA accumulation using Droplet Digital PCR (ddPCR). The combination of these tools allows precise and reliable quantitation of resection intermediates 22 . We selected a locus on Chromosome I and analyzed ssDNA accumulation at 364bp from DSB ends in U-2OS cells 22, 24 (Fig. 2a ). Importantly, all the ssDNA measurements through ddPCR were normalized on Cas9 cleavage efficiency to circumvent a potential decrease of cleavage efficiency in ATRi treated cells. Strikingly, VE-821 pretreatment caused a dosedependent reduction in the ssDNA signal detected by ddPCR ( Fig. 2b) , consistent with the prediction that the depletion of resection proteins is causing loss of resection capacity. In particular, the highest VE-821 dose tested caused a decrease in ssDNA accumulation comparable to the profound loss of resection observed in cells where BRCA1 has been depleted by siRNA ( Fig. 2c ). To confirm that the observed impairment of resection required multi-day long-term ATRi treatment, and is not due to a rapid effect of the ATR inhibitor, such as impairment of protein-protein interactions 46 , we also measured ssDNA after an acute and high-dose VE-821 treatment. Consistent with the idea that the gradual depletion of central resection factors, and not a short-term effect of ATR inhibition, acute inhibition of ATR or CHK1 for 8 hours only caused a minor reduction in ssDNA exposure ( Fig. 2d ).
Acute ATRi treatment did not cause any change in the abundance of BRCA1, CTIP, or BLM ( Fig. 2e ).
Because BRCA1 abundance is strongly affected by long-term ATR inhibition (Figs. 1a-d), we asked whether the impairment of resection was predominantly caused by the loss of BRCA1's function in counteracting the anti-resection factor 53BP1. Since 53BP1 inactivation restores resection and HR in BRCA1-deficient tumors [47] [48] [49] , we asked whether loss of 53BP1 could restore resection in cells treated chronically with ATR inhibitors. Consistent with previous works, we found that 53BP1 depletion by 8 siRNA significantly rescues resection in cells depleted for BRCA1, as measured by ddPCR at Cas9induced breaks ( Fig. 2f , g). Further analysis in U-2OS cells stably expressing inducible shRNA against 53BP1 and subjected to a 5-day pre-treatment with VE-821 revealed that 53BP1 inactivation does not accelerate resection speed upon long-term ATRi treatment ( Fig. 2h, i) . Therefore, loss of resection capacity in cells treated chronically with ATR inhibitors is not solely due to loss of BRCA1 but is likely a consequence of the loss of multiple important pro-resection factors. Overall, these results support the model whereby ATR inhibition severely impairs resection when cells undergo multiple cell divisions in the presence of ATR inhibitors (Fig. 2j ). The long-term treatment not only prevents the de novo synthesis of resection proteins by blocking the E2F-mediated transcription of new factors 17 but also allows for progressive degradation of the pre-existing pool (Fig. 2j ). In addition, these findings establish a key pro-resection function for ATR, especially in cancer cells undergoing intrinsically high levels of ATR-CHK1 signaling due to elevated oncogene-induced replication stress. In these cells, increased ATR signaling should drive increased resection capacity and increased engagement of HRmediated repair.
Long-term ATR inhibition impairs RAD51 and RAD52 localization to DNA damage-induced foci
Given the differences in resection capacity upon long-term versus acute ATR inhibition, we reasoned that these distinct modes of ATRi treatment should lead to different outcomes in how DNA lesions are repaired. Acute ATR inhibition was previously reported to impair RAD51 localization to IR-induced foci, which requires ATR-mediated phosphorylation of PALB2 and its subsequent interaction with BRCA1 16 . Since resection is only mildly affected upon acute ATR inhibition, we predicted that cells treated acutely with ATR inhibitors should still be proficient in utilizing Single Strand Annealing (SSA), a homology-directed repair pathway dependent on RAD52, but independent of RAD51-PALB2-BRCA2 50 . Consistent with this prediction, we found that acute VE-821 treatment impaired PARPiinduced RAD51 foci in U-2OS cells (Fig. 3a, b ), but did not alter PARPi-induced RAD52 foci ( Fig. 3c,   d ). As a positive control for the requirement of resection for SSA 51 , the ability of cells to form PARPi-induced RAD52 foci was severely impaired in cells treated with the MRN inhibitor Mirin (Fig. 3d ).
Importantly, and congruent with the requirement of resection for SSA, long-term ATRi treatment severely reduced RAD52 foci formation after PARPi treatment ( Fig. 3e, f ). Long-term ATRi treatment further diminished the number of cells with detectable RAD51 foci compared to an acute ATRi treatment ( Fig. 3g ). These findings highlight how acute and long-term ATR treatment can drastically shape distinct DNA repair outcomes. In a condition where ATR signaling is not inhibited, ATR promotes HR by maintaining the proper abundance of the HR machinery and by directly phosphorylating HR factors ( Fig. 3h ). Since direct phosphorylation of HR factors by ATR seems dispensable for resection, but essential for RAD51 loading, acute ATR inhibition still allows resection, which in turn enables the engagement of resection-dependent repair pathways, such as RAD52dependent repair ( Fig. 3i ). Long-term ATR inhibition leads to a distinct scenario, in which resection is severely blocked, therefore preventing both RAD51 and RAD52 engagement, and generally impairing any type of homology-directed repair ( Fig. 3i ).
Long-term ATR inhibition induces hypersensitivity to PARP inhibitors in a DNA-PKcsdependent manner
Since RAD51 or RAD52-dependent repair represent parallel HR pathways for promoting resistance to PARP inhibitors 50,52-55 , we reasoned that long-term ATR inhibition should lead to greater sensitization to PARP inhibitors as compared to acute ATR inhibition. To test this prediction, we monitored cell survival in cells subjected to a 5-day ATRi pre-treatment, followed by a 24-hour treatment with the PARP inhibitor Olaparib (Fig. 4a ). At the end of the 5-day ATRi pre-treatment, cells should be highly defective in resection and unable to utilize any HR pathway for repairing PARPi-induced DNA lesions ( Fig. 4a ). We tested the protocol in three distinct cell lines, two cancer cell lines (HCT116 and U-2OS), and an untransformed cell line (RPE1). Congruent with our hypothesis, we found that ATRi pretreatment increased the sensitivity of the two cancer cell lines to PARPi but did not increase sensitivity in the RPE1 cell line (Fig. 4b ).
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Since loss or delayed DNA end resection leads to prolonged binding of NHEJ machinery at DSB ends 56 , we reasoned that long-term ATRi treatment leads to increased DNA-PKcs activation and, consequently, to the pronounced use of NHEJ to repair PARPi-induced lesions. Strikingly, long-term ATR inhibition induced activation of DNA-PKcs and the magnitude of DNA-PKcs activation in the different cell lines correlated with the degree of sensitization to PARPi conferred by the long-term ATRi pre-treatment ( Fig. 4c ).
The results suggest that the increased sensitization to PARPi induced by long-term ATRi pretreatment is dependent on toxic NHEJ repair events that lead to loss of viability. Consistent with this possibility, we observed a significantly higher number of radial chromosomes, a typical output of toxic NHEJ of PARPi-induced breaks, in HCT116 cells exposed to the ATRi pre-treatment ( Fig. 4d ). Radial chromosomes after ATRi pre-treatment were NHEJ-dependent and where reduced by DNA-PK inhibition ( Fig. 4d ). In addition, the DNA-PKcs inhibitor NU7441 was able to rescue the sensitivity to PARPi conferred by the ATRi pre-treatment ( Fig. 4e ). Taken together, these findings support the model whereby ATRi pre-treatment induce hypersensitization to PARPi by allowing toxic NHEJmediated repair of DSBs. Of importance, the degree of sensitization to PARPi that is induced by longterm ATRi is distinct in different cell lines and directly correlates with the level of DNA-PKcs activation of each cell line.
Long-term ATR inhibition bypasses overexpression of E2F1
E2F transcription is often elevated in cancer by mutations in the pRb pathway 57 . Since long-term ATR inhibition affects the abundance of E2F targets 17 , many of which are components of the HR machinery, the ability of cancer cells to upregulate E2F transcription could, in principle, bypass the effects of long-term ATR inhibition. In this case, cancer cells would become refractory to the effects of ATR inhibition and resection factor abundance would not decrease. To verify whether elevated E2F 1 1 transcription could bypass the effects of long-term ATRi, we generated a conditional system to overexpress E2F1 using CRISPR/dCas9 transcriptional activation 58 . Using HCT116-dCas9-VP64 stable clones and five distinct sgRNAs targeting the E2F1 promoter, we were able to achieve robust overexpression of E2F1 ( Fig. 5a, b ). As expected, overexpression of E2F1 was associated with an increase in the abundance of several E2F targets ( Fig. 5b) . As a control, the abundance of 53BP1, whose expression is not regulated by E2F1, remained unaltered. Next, we subjected HCT116-dCas9-VP64 control or E2F1 overexpressing cells to a 5-day treatment with the ATRi AZD6738.
Unexpectedly, long-term treatment with AZD6738 overcame high E2F1 expression and led to the efficient and gradual depletion of BRCA1 and CTIP resection factors (Fig. 5c ). These results indicate that long-term ATRi treatment depletes DNA end resection factors independently of E2F1 status, suggesting that altering E2F expression does not represent a mechanism by which cancer cells may become refractory to changes in resection factors induced by long-term ATRi treatment. 1 2 Discussion 5'-3' DNA end resection is a crucial step in defining DNA repair outcomes. The ability to manipulate resection capacity is expected to be a powerful strategy to rationally modulate DNA repair outcomes in cancer cells and induce selective cell lethality. Here we report that ATR inhibitors can be used as potent modulators of DNA end resection. We further build on this finding to define how ATRi-induced resection loss promotes hypersensitivity to PARP inhibitors. Since PARP inhibitors are already FDA approved drugs used in cancer therapy, and ATR inhibitors are already in phase II clinical trials, our work should be directly applicable to the better design of drug treatment regimes. In particular, the understanding that long-term ATR inhibition promotes a resection block that forces NHEJ repair of PARPi-induced lesions reveals a defined rationale for enhancing the effectiveness of these inhibitors.
These findings establish a new role for ATR in modulating DNA end resection capacity. While previous studies elucidated the contribution of ATM and DNA-PKcs in resection initiation 24, 59 , it was still unclear whether ATR contributes to DNA end resection. Part of this knowledge gap is caused by the employment of RPA or thymidine analog-based assays to visualize resection intermediates, which might conflict with the ATR role in suppressing origin firing and buffering RPA pool 60 . Here, employing a CRISPR-Cas9-based resection assay 22 , we found that up to 24 hours of ATR inhibition (acute inhibition) only caused a minor reduction in ssDNA accumulation. These findings are also in line with the established hierarchical mode of kinase activation at resected breaks, whereby ATR activation occurs after ATM signaling [26] [27] [28] [29] [30] . A modest reduction in ssDNA accumulation is still appreciable after acute ATR inhibition, indicating that ATR has a direct role in DNA end resection. Consistent with this idea, we have previously proposed that, upon recruitment and activation, ATR promotes an interaction between BRCA1 and the TOPBP1 scaffold to form a pro-resection complex that counteracts 53BP1dependent resection inhibition 46 . While acute ATR inhibition has minor effects on resection, it does lead to severe reduction in RAD51 loading, as previous reported 16, 61 , and confirmed here ( Fig. 3a, b ). 1 3 Interestingly, however, the inability of acute ATRi treatment to impair DNA end resection allows the engagement of RAD52-dependent pathways that mitigate the cytotoxic effect of PARP inhibitors and other drugs. Previous studies have shown that RAD52-mediated repair could compensate for loss of HR in cells lacking the PALB2-BRCA2 machinery and therefore, could represent a mechanism of resistance to acute treatments with PARP inhibitors and ATR inhibitors 52, 54, 55, 62 . Notably, RAD52 was reported to foster RAD51-dependent recombination in brca2-deficient cells 52 , therefore bypassing the requirement of PALB2 phosphorylation by ATR and possibly explaining the residual levels of RAD51 foci observable after acute ATRi and PARPi. Moreover, acute ATR inhibition has been shown to disrupt restored RAD51 foci and HR in brca1 53bp1 cells after PARPi treatment 18 . Because 53bp1deficient cells have a pronounced preference for RAD52-mediated repair 63 , we predict that acute ATR inhibition would still allow RAD52-dependent pathways to occur in brca1 53bp1 cells. In this sense, the ability of long-term ATRi treatments to inhibit both RAD51 and RAD52-dependent DNA repair provides the mechanistic rationale to utilize ATRi in treating HR-deficient tumors with acquired resistance to PARPi and other drugs. While it is still unclear whether the loss of a specific factor is responsible for the decrease in DNA end resection capacity upon long-term ATRi, our data suggest that loss of resection capacity upon long-term ATRi treatment is complex and due to loss of multiple pro-resection factors rather than loss of one specific factor, such as BRCA1. This is supported by our experiments showing that loss of 53BP1 does not increase resection efficiency upon long-term ATR inhibition. While loss of 53BP1 can restore HR and RAD51 foci in brca1 cells 47 , it fails to do so in cells depleted of other resection factors such as CtIP 48, 64 . Since the inability to promote resection upon long-term ATR inhibition could be due to the combined loss of BRCA1, CtIP, and additional proresection factors, we do not expect that restoring any specific factor alone is enough to restore resection.
Our findings strongly support the model whereby a decrease in DNA end resection and HR capacity upon long-term ATR inhibition leads to increased engagement of DNA-PKcs at DNA ends caused by 1 4 PARPi, which promotes increased NHEJ, chromosomal aberrations, and cell death. Congruent with this model, we find that inhibition of DNA-PKcs restores cell viability in cells treated chronically with ATRi. This finding is also consistent with previous reports showing that genetic and chemical ablation of DNA-PKcs can suppress the formation of radial chromosomes in HR-deficient cancers and Fanconi Anemia patient-derived cells 65, 66 . These reports and our findings raise the question of how cells deprived of both HR and NHEJ repair pathways survive to PARPi treatment. We propose that the engagement of DNA-PKcs at DNA breaks prevents any resection and rapidly directs DNA repair toward NHEJ, and that inhibition of DNA-PKcs allows time for residual resection to eventually occur, which in turn allows microhomology-mediated end joining (MMEJ) repair events. In the future, to understand the mechanism of DNA-PKcs-induced cell lethality, it would be essential to identify the DNA-PKcs target(s) through which DNA-PKcs promotes NHEJ. In particular, such analysis should be performed in the context of cells treated with ATRi, which might expand the spectrum of DNA-PKcs substrates, including proteins that are normally not targeted by the kinase. While other studies previously observed DNA-PKcs activation after ATR inhibition 12, 67 , it is still unclear what DNA structures arising after ATR inhibition trigger DNA-PKcs activation in cells. A possible scenario is that the gradual decrease in resection capacity caused by long-term suppression of ATR signaling leads to a progressive engagement of DNA-PKcs at DNA breaks naturally forming during DNA replication or as a consequence of ATR inhibition. Also, DNA breaks could arise from extensive degradation of stalled replication forks, since long-term ATR inhibition could deplete the abundance of fork protection factors such as BRCA1/2 17 . As a consequence, extensive fork degradation allows the SLX4-MUS81 nuclease complex to cleave replication forks leading to DNA-PKcs activation 12, 68, 69 . According to our data, DNA-PKcs activation by long-term ATRi pretreatment is not only a key event in the sensitization of cancer cells to PARP inhibitors but also the magnitude of DNA-PKcs activation/signaling could be considered as a predictive marker of long-term ATRi efficacy in sensitizing cancer cells to PARP inhibitors. These findings provide mechanistic rationales for the design of more effective inhibitor treatment regimes and to better predict the treatment efficiency based on the levels of DNA-PKcs activation. 1 5 Modulation of the E2F-dependent transcription program is at the heart of the observed effects of longterm ATR inhibition. E2F-dependent transcription has a range of relevant implications to understand cancer proliferation and the ability of cancer cells to withstand high levels of endogenous and genotoxin-induced replication stress. E2F transcription is increased by oncogenic mutations that alleviate the pRb inhibitory activity on E2F1 (mutations on pRb or CDKN2A, for instance). In addition, increased E2F-transcription is a common feature of cancers undergoing increased levels of intrinsic replication stress and ATR signaling 32, 70 . We further speculate that E2F transcription is also induced in tumors undergoing repeated cycles of chemotherapy, and that increases in the E2F-dependent transcriptional program represent a potential source of resistance to anticancer drugs. In agreement with this idea, a recent study showed that a pre-exposure to cisplatin is sufficient to induce an ATRdependent adaptive response to subsequent cisplatin treatments that involves transcription of the PRIMPOL protein to rescue fork degradation in brca1 cancer cells 71 . This finding is in line with our model positioning ATR as a sensor of intrinsic or drug-induced replication stress and a regulator of genome stability through the modulation of the E2F transcription program and HR-coupled repair.
Importantly, our ability to overcome induced E2F1 overexpression by long-term ATR inhibition indicates that resection and HR capacity can be remodeled independently of the levels of E2F transcription. This finding should be relevant to addressing ATRi-mediated therapies in tumors that are highly dependent on E2F transcription or in tumors that have built an adaptive response to chemotherapy 71, 72 .
In the future, it will be essential to transfer the knowledge accumulated about the effect of long-term ATR inhibition to more complex systems such as tumor organoids and, more importantly, to mouse models of human cancers. To date, an effective strategy to inhibit DNA end resection with high tolerability and minimized side effects in patients is still missing. Long-term ATR inhibition represents 1 6 an innovative and efficient strategy to inhibit DNA end resection and manipulate DNA repair outcomes in many cancers. Millipore) was used at 25μM concentration. Auxin (IAA, Sigma Millipore) was used at a 10µg/ml concentration.
Antibodies. The antibodies used in this study are: BRCA1 73 Supplementary Table 1 ). Lentivirus for each sgRNA were produced in 293T cells using standard procedures. HCT116-dCas9-VP64 stable clone was transduced with viral pools containing five different sgRNAs specific for the E2F1 promoter. Viral transduction was then followed by selection with G418 (700µg/ml) for 3-5 days.
Cell viability assay. U-2OS, HCT116, or RPE1 cells were treated for 5 days with DMSO or 2.5 µM VE-821, refreshing media on days 2 and 4. Then either 1 x 10 5 cells were passaged in new plates with media containing DMSO, VE-821 (2.5 µM), Olaparib (2.5 µM or 5 µM), or a combination of VE-821
and Olaparib. Cells were treated in these conditions for 24 hours, after which the drugged media was removed, allowing the cells to recover for 8 days in drug-free media. After the recovery period, live cell Immunofluorescence and Microscopy Analysis. U-2OS cells were grown on coverslips and treated with the indicated combination of acute/chronic ATRi and PARPi treatment. Cells were then fixed with 3.7% formaldehyde in PBS for 10min at RT. Fixed cells were then washed three times with PBS, permeabilized 5 minutes with 0,2% Triton-X100/PBS at RT and blocked in 10%BSA/PBS 20 minutes at RT. Coverslips were incubated first with primary antibodies for 2 hours at RT, followed by three washes with PBS, and then for 1 hour with relative secondary antibodies (Alexa Fluor488 Goat anti-Mouse IgG (H+L) and Alexa Fluor568 Donkey anti-Rabbit IgG (H+L), Thermo Fisher Scientific). After incubation with secondary antibody, coverslips were washed three times with PBS and then mounted on glass microscope slides using DAPI-Vectashield mounting medium (Vector Laboratories).
Microscope slides were imaged using a Leica DMi8 inverted fluorescent microscope with a 63X objective. For RAD51 and RAD52 foci scoring, approximately 150-200 cells/replicate were counted and the fraction of cells with more than 5 distinct RAD51 foci or 10 distinct RAD52 foci was determined. The two-tailed Student's t test was used for statistical analysis. 
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